ALBERT

All Library Books, journals and Electronic Records Telegrafenberg

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Publication Date: 2020
    Description: 〈p〉Publication date: April 2020〈/p〉 〈p〉〈b〉Source:〈/b〉 Biochemical Pharmacology, Volume 174〈/p〉 〈p〉Author(s): Xiaohan Zhang, Xiao Min, Anlin Zhu, Kyeong-Man Kim〈/p〉 〈div xml:lang="en"〉 〈h5〉Abstract〈/h5〉 〈div〉〈p〉Protein kinase C (PKC) is one of the major effectors involved in the heterologous regulatory pathways of G protein-coupled receptors (GPCRs). On the other hand, GRK2 and β-arrestins are the players of homologous regulatory pathway of GPCRs that affect the receptor functions in agonist-selective manner. Even though two pathways can occur independently, crosstalks between two pathways add more diverse modes of regulations on GPCR functions. Even if extensive studies have been conducted, a commonly applicable molecular mechanism involved in the crosstalks between two regulatory pathways has yet to be elucidated. Here we show that PKCβII was phosphorylated at its activation loop of kinase domain (T500) through constitutive interaction with phosphoinositide-dependent kinase 1 (PDK1) that is phosphorylated at S214. With agonist stimulation, dopamine D〈sub〉2〈/sub〉 receptor interacted with 14-3-3η in GRK2/β-arrestin2-dependent manner, resulting in the recruitment of PDK1. The PDK1 recruited to 14-3-3η was dephosphorylated at S241 and dissociated from PKCβII, abrogating the phosphorylation of PKCβII at T500. This signaling cascade resulted in the inhibition of PKCβII functions, including its phosphorylation in the C-terminal tail, intracellular translocation, and kinase activity. Thus, this study revealed a novel and commonly applicable molecular mechanism involved in the inhibition of PKCβII functions through GRK2/β-arrestin2-mediated homologous pathway of GPCRs. The results obtained in this study could be expanded to other GPCRs and provide new strategies for the treatment of PKCβII-related disorders.〈/p〉〈/div〉 〈/div〉 〈div xml:lang="en"〉 〈h5〉Graphical abstract〈/h5〉 〈div〉〈p〉〈figure〉〈img src="https://ars.els-cdn.com/content/image/1-s2.0-S0006295220300010-ga1.jpg" width="364" alt="Graphical abstract for this article" title=""〉〈/figure〉〈/p〉〈/div〉 〈/div〉
    Print ISSN: 0006-2952
    Electronic ISSN: 1873-2968
    Topics: Biology , Chemistry and Pharmacology , Medicine
    Published by Elsevier
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...